NJ State Employees Deferred Compensation Plan’s Celldex Therapeutics CLDX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,333	Closed	-$16K	–	541
2018 Q4	$16K	Hold	5,333	–	–	﹤0.01%	514
2018 Q3	$36K	Hold	5,333	–	–	0.01%	513
2018 Q2	$40K	Hold	5,333	–	–	0.01%	498
2018 Q1	$186K	Hold	5,333	–	–	0.03%	453
2017 Q4	$227K	Hold	5,333	–	–	0.04%	441
2017 Q3	$229K	Sell	5,333 -1,334	-20%	-$50K	0.04%	424
2017 Q2	$247K	Hold	6,667	–	–	0.05%	372
2017 Q1	$361K	Hold	6,667	–	–	0.07%	308
2016 Q4	$354K	Hold	6,667	–	–	0.07%	301
2016 Q3	$404K	Hold	6,667	–	–	0.08%	284
2016 Q2	$439K	Hold	6,667	–	–	0.09%	281
2016 Q1	$489K	Hold	6,667	–	–	0.1%	269
2015 Q4	$1.57M	Hold	6,667	–	–	0.32%	91
2015 Q3	$1.05M	Hold	6,667	–	–	0.23%	149
2015 Q2	$2.52M	Hold	6,667	–	–	0.49%	47
2015 Q1	$2.79M	Hold	6,667	–	–	0.54%	41
2014 Q4	$1.82M	Hold	6,667	–	–	0.36%	71
2014 Q3	$1.3M	Hold	6,667	–	–	0.26%	111
2014 Q2	$1.63M	Hold	6,667	–	–	0.32%	83
2014 Q1	$1.77M	Hold	6,667	–	–	0.36%	66
2013 Q4	$2.42M	Hold	6,667	–	–	0.49%	39
2013 Q3	$3.54M	Hold	6,667	–	–	0.77%	16
2013 Q2	$1.56M	Buy	+6,667	New	+$1.31M	0.36%	72

Other funds holding CLDX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's CLDX Position: Q1 2019 in Review

NJ State Employees Deferred Compensation Plan sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 5,333 shares — an estimated $16K sold.

NJ State Employees Deferred Compensation Plan first reported a position in CLDX in Q2 2013 and held it in 23 quarters. The position peaked at $3.54M in Q3 2013. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

NJ State Employees Deferred Compensation Plan reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 5,333 Celldex Therapeutics shares in Q1 2019, an estimated $16K.
NJ State Employees Deferred Compensation Plan first reported a position in Celldex Therapeutics in Q2 2013 and held it in 23 quarters.
NJ State Employees Deferred Compensation Plan's Celldex Therapeutics position peaked at $3.54M in Q3 2013.
53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q1 2019, filed 1 May 2019.